Stock purchase agreement under which the Company agreed to sell 15,652,173 shares of Common Stock to Medtronic in a private placement.
| Officer | Age | In this role | 2025 pay | Source |
|---|---|---|---|---|
|
Wayne Paterson
Also a director
Vice Chairman and Chief Executive Officer
|
60 | Not stated | $6,131,101 | |
|
Brent Moen
Chief Financial Officer
|
59 |
Since 2026
this year
|
Not reported | |
|
David St Denis
Also a director
President, Director
|
58 |
Since 2025
1 year
|
$981,905 | |
|
Matthew McDonnell
Head of Australia
|
54 |
Since 2026
this year
|
$457,352 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Stock purchase agreement under which the Company agreed to sell 15,652,173 shares of Common Stock to Medtronic in a private placement.
Registration rights agreement requiring the Company to file a resale registration statement for Medtronic's shares, with liquidated damages payable if registration fails, capped at 5.0% of the purchase price.
Investor rights agreement granting Medtronic participation rights, transfer restrictions, a collaboration framework, standstill, voting agreement, board observer right and a right to negotiate.
Loading...